Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 11 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 54% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $390,440, and 7 were calls, valued at $661,335.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $130.0 and $220.0 for Alnylam Pharmaceuticals, spanning the last three months.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Alnylam Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Alnylam Pharmaceuticals's substantial trades, within a strike price spectrum from $130.0 to $220.0 over the preceding 30 days.
Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNY | CALL | TRADE | BULLISH | 08/16/24 | $29.5 | $28.1 | $29.5 | $165.00 | $295.0K | 95 | 115 |
| ALNY | PUT | SWEEP | BULLISH | 07/19/24 | $21.4 | $21.0 | $21.0 | $150.00 | $210.0K | 1.1K | 250 |
| ALNY | CALL | TRADE | BULLISH | 08/16/24 | $10.0 | $8.5 | $10.0 | $220.00 | $110.0K | 983 | 0 |
| ALNY | PUT | SWEEP | BULLISH | 07/19/24 | $30.0 | $27.7 | $27.7 | $165.00 | $105.2K | 199 | 0 |
| ALNY | CALL | TRADE | BEARISH | 08/16/24 | $11.6 | $10.5 | $10.5 | $220.00 | $105.0K | 983 | 110 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
In light of the recent options history for Alnylam Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Alnylam Pharmaceuticals
- With a trading volume of 345,641, the price of ALNY is down by -1.65%, reaching $157.75.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 45 days from now.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
